| |
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
|
| |
| |
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
Glecaprevir/pibrentasvir for 6 weeks was highly effective, safe, and well tolerated among people with acute and recent HCV infection (SVR12 ITT 90%, SVR12 PP 96%), including among people with HIV coinfection and high baseline HCV RNA (>6 log10 IU/mL). Treatment resulted in rapid HCV RNA suppression and normalization of liver enzymes. No treatment-related serious adverse events were reported.
| |
| |
| |
|
|
|
